FindTrial
Sign In

The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer

The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer - The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000044937
Enrollment
2000
Registered
2021-07-21
Start date
2021-07-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Sponsors

Osaka University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: NSCLC patients who received immune checkpoint inhibitors and anti-angiogenic agents combination therapy or either monotherapy

Exclusion criteria

Exclusion criteria: Patients without data about survival or tumor response

Design outcomes

Primary

MeasureTime frame
The primary endopoint are overall survival, progression-free survival,and overall response rate.—

Countries

Japan

Contacts

Public ContactKinnosuke Matsumoto

Osaka University Graduate School of Medicine Department of Pulmonology

m.kinnosuke@gmail.com+810668793831

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026